What daily oral dose of aripiprazole (Abilify Maintena) 400 mg monthly injection is equivalent to?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Abilify Maintena 400 mg Monthly Equivalent Oral Dose

Abilify Maintena 400 mg administered monthly is equivalent to oral aripiprazole 15-20 mg daily.

Pharmacokinetic Basis

The FDA-approved prescribing information for Abilify Maintena establishes that the 400 mg monthly intramuscular injection is the standard maintenance dose 1. Based on observed pharmacokinetic data, minimum aripiprazole concentrations achieved by Abilify Maintena 400 mg are comparable with those of oral aripiprazole 15-20 mg daily 2.

Multiple pharmacokinetic studies confirm this equivalence:

  • The plasma concentration profile of aripiprazole after initiating Abilify Maintena 400 mg was consistent with therapeutic concentrations observed with oral aripiprazole 10-30 mg/day, with mean concentrations after 4 weeks (93-112 ng/mL) falling within the established therapeutic window (94.0-534.0 ng/mL) 3

  • Administration of Abilify Maintena 300 mg and 400 mg provided sustained mean aripiprazole plasma concentrations comparable with the concentration range observed following multiple consecutive daily doses of oral aripiprazole 4

Clinical Trial Evidence

The efficacy and safety of Abilify Maintena 400 mg in pivotal maintenance studies were comparable between patients previously stabilized on either 10 mg or 30 mg daily doses of oral aripiprazole 3. This demonstrates that the 400 mg monthly injection provides therapeutic coverage across the oral dosing range.

A randomized controlled trial demonstrated that Abilify Maintena 400 mg was non-inferior to oral aripiprazole 10-30 mg/day in preventing relapse, with Kaplan-Meier estimated impending relapse rates at week 26 of 7.12% versus 7.76% respectively 5.

Initiation Considerations

When initiating Abilify Maintena 400 mg, the FDA label specifies two options 1:

  • 1-day initiation: Two separate 400 mg IM injections plus a single 20 mg oral dose
  • 14-day initiation: One 400 mg IM injection with 14 consecutive days of oral aripiprazole 10-20 mg

Recent evidence suggests the two-injection start (TIS) regimen may be associated with serum levels within the therapeutic window while avoiding peaks above the window that occurred with the one-injection start regimen 6.

Dose Adjustments

The dose can be reduced to 300 mg monthly in patients with adverse reactions 1. For known CYP2D6 poor metabolizers, the recommended starting and maintenance dose is 300 mg monthly 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.